Location History:
- Boulogne Billancourt, FR (2017 - 2020)
- Paris, FR (2021)
Company Filing History:
4 out of 4,872 
1 out of 1 Years Active: 2017-2021
Title: The Innovative Contributions of Franck Mouthon
Introduction
Franck Mouthon, an accomplished inventor based in Boulogne Billancourt, France, has made significant strides in the field of pharmaceuticals with a focus on neuropsychiatric treatments. With a diverse portfolio of four patents, Mouthon has dedicated his research to enhancing the therapeutic effects of psychotropic drugs through innovative approaches.
Latest Patents
Among his notable inventions is the patent titled "Use of anti-connexin agents for modulating the therapeutic effect of psychotropic drugs." This groundbreaking invention involves the combination of connexin-blocking agents and psychotropic drugs, aiming to aid patients suffering from psychiatric and neurodegenerative disorders. Notable connexin-blocking agents identified include meclofenamic acid, 18-β-glycyrrhetinic acid, carbenoxolone, mefloquine, and 2-APB, with a preference for meclofenamic acid.
Another significant patent by Mouthon is "Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitors." This innovation enhances neurological and neuropsychic treatments by potentiating the effects of reversible acetylcholinesterase inhibitors, specifically using connexin-blocking agents such as meclofenamic acid.
Career Highlights
Franck Mouthon has worked with esteemed organizations such as the Commissariat à l'Énergie Atomique et aux Énergies Alternatives (CEA) and Bio Modeling Systems, which have contributed to his expertise and innovative mindset. His experience in these reputable institutions has bolstered his research capabilities and fostered a productive environment for his inventions.
Collaborations
Throughout his career, Mouthon has collaborated with notable individuals, including Mathieu Charveriat and Jean-Philippe Deslys. These partnerships have likely facilitated the exchange of ideas and innovations, further enriching his contributions to the pharmaceutical domain.
Conclusion
In summary, Franck Mouthon has established himself as a prominent inventor in the realm of psychotropic drug therapies through his innovative patents. His work continues to pave the way for advancements in the treatment of psychiatric and neurodegenerative disorders, highlighting the importance of innovative thinking in the medical field. As he continues to push the boundaries of pharmaceutical science, Mouthon exemplifies the drive and dedication essential for lasting impact in today’s world.